February 26,2020
Prescription Drug Middleman Cigna Has So Far Failed to Produce Records
Washington – Senate Finance Committee Chairman Chuck Grassley
(R-Iowa) and Ranking Member Ron Wyden (D-Ore.) today wrote
to the president of Express Scripts, a pharmacy benefit manager (PBM) owned by the Cigna
Corporation, making a
final request for documents as part of the committee’s investigation into
skyrocketing insulin prices. The leaders of the committee wrote that their
letter would serve as final notice and a failure to comply would result in a
subpoena compelling their production.
(R-Iowa) and Ranking Member Ron Wyden (D-Ore.) today wrote
to the president of Express Scripts, a pharmacy benefit manager (PBM) owned by the Cigna
Corporation, making a
final request for documents as part of the committee’s investigation into
skyrocketing insulin prices. The leaders of the committee wrote that their
letter would serve as final notice and a failure to comply would result in a
subpoena compelling their production.
“Americans
are demanding answers from PBMs and pharmaceutical companies, and we expect
your company to begin providing them promptly,” Grassley and Wyden wrote. “Cigna
has failed to even attempt to answer many of the questions we posed.”
“Your
failure to comply with the Committee’s requests has reached an endpoint,” Grassley
and Wyden concluded.
Grassley
and Wyden have engaged Cigna for nearly a year and have not received a
satisfactory production of information in response to their requests. Their
letter can be found HERE.
and Wyden have engaged Cigna for nearly a year and have not received a
satisfactory production of information in response to their requests. Their
letter can be found HERE.
In
February 2019, Grassley and Wyden began their
bipartisan investigation into the rapidly rising price of insulin in the
United States by questioning the three leading insulin manufacturers. In April
2019, Grassley and Wyden sent
three letters to leading PBMs, including one to Cigna, regarding their role
in the high price of insulin. Cigna was one of five
PBMs represented at an April committee hearing
regarding the role of prescription drug middlemen in the drug supply chain.
February 2019, Grassley and Wyden began their
bipartisan investigation into the rapidly rising price of insulin in the
United States by questioning the three leading insulin manufacturers. In April
2019, Grassley and Wyden sent
three letters to leading PBMs, including one to Cigna, regarding their role
in the high price of insulin. Cigna was one of five
PBMs represented at an April committee hearing
regarding the role of prescription drug middlemen in the drug supply chain.
The
Senate Finance Committee has jurisdiction over Medicare and Medicaid. Taxpayers
spend hundreds of billions of dollars annually on each federal program,
including on prescription drugs. PBMs generate significant business from
Medicare and Medicaid.
Go to Source
Author: